Advanced Solid Tumors: RMC-6291 and RMC-6236 Combination Study

We are examining how well different doses of RMC-6291 and RMC-6236 are tolerated by people with advanced KRASG12C-mutated solid tumors. This study aims to gather important safety information about this treatment combination.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Institut De Cancerologie De L Ouest
Oncology Department
Angers, France
Institut Bergonie
Medical Oncology
Bordeaux, France
Hospices Civils De Lyon
Pulmonology
Bron, France

Sponsor: Revolution Medicines Inc.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.